The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Elizabeth Blair and Daniel T. Ginat.
Connection Strength

2.977
  1. Nasal cavity tumefactive fibroinflammatory lesion mimicking recurrent mucoepidermoid carcinoma. Ear Nose Throat J. 2017 Aug; 96(8):290-293.
    View in: PubMed
    Score: 0.618
  2. Concurrent fungus ball and squamous cell carcinoma of the maxillary sinus. Eur Ann Otorhinolaryngol Head Neck Dis. 2016 Apr; 133(2):153-4.
    View in: PubMed
    Score: 0.554
  3. Laryngeal Swelling. JAMA Otolaryngol Head Neck Surg. 2015 Jul; 141(7):667-8.
    View in: PubMed
    Score: 0.535
  4. A painful lesion of the mandible. Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Sep; 132(4):237-8.
    View in: PubMed
    Score: 0.530
  5. Imaging features and surgical management of giant parathyroid adenoma with autoinfarction. J Clin Imaging Sci. 2024; 14:9.
    View in: PubMed
    Score: 0.245
  6. Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib. Int J Surg Pathol. 2017 Oct; 25(7):613-618.
    View in: PubMed
    Score: 0.152
  7. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Clinical Trial. JAMA Oncol. 2024 Jun 06.
    View in: PubMed
    Score: 0.062
  8. Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits. Cureus. 2022 Jul; 14(7):e27521.
    View in: PubMed
    Score: 0.055
  9. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
    View in: PubMed
    Score: 0.052
  10. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566.
    View in: PubMed
    Score: 0.052
  11. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 10 01; 30(10):1673.
    View in: PubMed
    Score: 0.045
  12. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
    View in: PubMed
    Score: 0.043
  13. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.